Next Article in Journal
Preliminary Results of an Exercise Program After Laparoscopic Resective Colorectal Cancer Surgery in Non-Metastatic Adenocarcinoma: A Pilot Study of a Randomized Control Trial
Next Article in Special Issue
CPAP Effect on Cardiopulmonary Exercise Testing Performance in Patients with Moderate-Severe OSA and Cardiometabolic Comorbidities
Previous Article in Journal
De novo NIPBL Mutations in Vietnamese Patients with Cornelia de Lange Syndrome
Previous Article in Special Issue
The Association of Obstructive Sleep Apnea Syndrome and Accident Risk in Heavy Equipment Operators
Open AccessArticle

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea

Department of Pulmonology, Semmelweis University, 1083 Budapest, Hungary
Department of Pulmonology, Szent Borbala County Hospital, 2800 Tatabánya, Hungary
Medical Imaging Centre, Semmelweis University, 1082 Budapest, Hungary
North West Lung Centre, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK
Author to whom correspondence should be addressed.
Medicina 2020, 56(2), 77;
Received: 4 January 2020 / Revised: 27 January 2020 / Accepted: 5 February 2020 / Published: 14 February 2020
(This article belongs to the Special Issue Obstructive Sleep Apnea: Epidemiology, Pathomechanism and Treatment)
Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods: A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results: There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions: Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR. View Full-Text
Keywords: biomarkers; fibrinolysis; inflammation; OSAHS; sleep disordered breathing biomarkers; fibrinolysis; inflammation; OSAHS; sleep disordered breathing
Show Figures

Figure 1

MDPI and ACS Style

Bocskei, R.M.; Meszaros, M.; Tarnoki, A.D.; Tarnoki, D.L.; Kunos, L.; Lazar, Z.; Bikov, A. Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea. Medicina 2020, 56, 77.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop